The breast cancer network model we present in this work integrates the current knowledge of PIK3CA-mutant, ER+ breast cancers, and uses it to identify a set of elements that may eventually be exploited in high-order therapeutic combinations to achieve a more durable control of breast cancer. This evidence concerns the gene PIK3CA and breast carcinoma.